DEMIAN OBREGON, MD
Psychiatric in Tampa, FL
License number
Florida ME110687
Category
Psychiatric
Type
Child & Adolescent Psychiatry
Address
Address
3515 E. Fletcher Ave. Mdc14, Tampa, FL 33613
Phone
(813) 974-1393
Personal information
See more information about DEMIAN OBREGON at radaris.comName
Address
Phone
306 E Chelsea St, Tampa, FL 33603
Tampa, FL
2135 22Nd Ave N, Saint Petersburg, FL 33713
2159 22Nd Ave N, Saint Petersburg, FL 33713
306 Chelsea St, Tampa, FL 33603
Professional information
Transgenic Model Of Alzheimer's Disease
US Patent:
2013029, Oct 31, 2013
Filed:
Jun 25, 2013
Appl. No.:
13/926610
Inventors:
Jun Tan - Tampa FL, US
Demian Forest Obregon - Tampa FL, US
Huayan Hou - Tampa FL, US
Demian Forest Obregon - Tampa FL, US
Huayan Hou - Tampa FL, US
Assignee:
UNIVERSITY OF SOUTH FLORIDA - Tampa FL
International Classification:
A01K 67/027
US Classification:
800 12, 800 22
Abstract:
Evidence indicates dysregulation. of the immunoregulatory molecule CD45 occurs in Alzheimer's disease (AD). Transgenic mice overproducing amyloid-β peptide (Aβ) and deficient in CD45 (PSAPP/CD45/) recapitulate AD neuropathology. Increased cerebral intracellular and extracellular soluble oligomeric and insoluble Aβ, decreased plasma soluble Aβ increased microglial neurotoxic cytokines TNF-α and IL-1β, and neuronal loss were found in PSAPP/CD45/ mice compared with CD45-sufficient PSAPP littermates. After CD45 ablation, in vitro and in vivo studies demonstrate a microglial phenotype whereby microglia phagocytose less Aβ but display proinflammatory properties. This microglial activation occurs with elevated Aβ oligomers and neural injury and loss as determined by decreased ratio of anti-apoptotic Bcl-xL to proapoptotic Bax, increased activated caspase-3, mitochondrial dysfunction, and loss of cortical neurons in PSAPP/CD45/ mice. These data show that deficiency in CD45 activity leads to brain accumulation of neurotoxic Aβ oligomers and validate CD45-mediated microglial clearance of oligomeric Aβ as a novel AD therapeutic target.
Dr. Demian Obregon, Saint Petersburg FL - MD (Doctor of Medicine)
Specialties:
Child & Adolescent Psychiatry
Address:
880 6Th St S SUITE 420, Saint Petersburg 33701
(727) 767-8477 (Phone), (727) 767-8244 (Fax)
UNIV OF SOUTH FLORIDA DEPT PSYCHIATRY & BEHAVIORAL MED
3515 E Fletcher Ave, Tampa 33613
(813) 974-8900 (Phone), (813) 974-3223 (Fax)
THE ROTHMAN CENTER
800 6Th St S SUITE 7523, St Petersburg 33701
(727) 767-8230 (Phone), (727) 767-7786 (Fax)
(727) 767-8477 (Phone), (727) 767-8244 (Fax)
UNIV OF SOUTH FLORIDA DEPT PSYCHIATRY & BEHAVIORAL MED
3515 E Fletcher Ave, Tampa 33613
(813) 974-8900 (Phone), (813) 974-3223 (Fax)
THE ROTHMAN CENTER
800 6Th St S SUITE 7523, St Petersburg 33701
(727) 767-8230 (Phone), (727) 767-7786 (Fax)
Languages:
English
Education:
Medical School
University of South Florida / College of Medicine
Graduated: 2007
University of South Florida / College of Medicine
Graduated: 2007
Demian Obregon, Tampa FL
Specialties:
Psychiatry
Work:
James a Haley Veterans' Hospital
13000 Bruce B Downs Blvd, Tampa, FL 33612 Bay Pines Va Healthcare System
10000 Bay Pines Blvd, Bay Pines, FL 33744
13000 Bruce B Downs Blvd, Tampa, FL 33612 Bay Pines Va Healthcare System
10000 Bay Pines Blvd, Bay Pines, FL 33744
Demian Obregon, Tampa FL
Specialties:
Child and Adolescent Psychiatrist
Address:
3515 E Fletcher Ave, Tampa, FL 33613
Use Of Functional Autoantibodies In Alzheimer Disease
US Patent:
2013021, Aug 22, 2013
Filed:
Feb 15, 2013
Appl. No.:
13/768158
Inventors:
Jun Tan - Tampa FL, US
Demian Obregon - Tampa FL, US
Huayan Hou - Tampa FL, US
Juan Deng - Tampa FL, US
Demian Obregon - Tampa FL, US
Huayan Hou - Tampa FL, US
Juan Deng - Tampa FL, US
Assignee:
University of South Florida (A Florida Non-Profit Corporation) - Tampa FL
International Classification:
G01N 33/68
US Classification:
435 792, 435 71
Abstract:
Provided herein is a method for diagnosing Alzheimer's disease in a subject comprising detecting an increase in an amyloidogenic Aβantibody in the subject as compared to a control. Further provided herein is a method for testing efficacy of an Alzheimer's disease treatment in a subject comprising detecting a decrease in an amyloidogenic Aβantibody in the subject as compared to prior to the treatment.
Sapp-Alpha As A Biomarker For Prediction Of Inflammatory And Autoimmune-Related Disorders
US Patent:
2013016, Jun 27, 2013
Filed:
Jun 30, 2011
Appl. No.:
13/704921
Inventors:
Jun Tan - Tampa FL, US
Demian Obregon - Tampa FL, US
Antoinette Bailey - Tampa FL, US
Demian Obregon - Tampa FL, US
Antoinette Bailey - Tampa FL, US
Assignee:
UNIVERSITY OF SOUTH FLORIDA - TAMPA FL
International Classification:
G01N 33/68
US Classification:
506 9, 436501, 435 792, 435 79
Abstract:
The subject invention pertains to the use of amyloid precursor protein-alpha (sAPP-α) as a biomarker for prediction of a subject's risk of developing inflammatory and/or autoimmune-related disorders. In addition, the present invention provides methods for optimizing vaccine schedules and compositions, thereby preventing or reducing the risks of vaccine-induced inflammatory and/or autoimmune-related disorders.